Inhandplus

The global clinical trial market is projected to grow at an annual rate of 5.7% through 2030, with the decentralized clinical trial (DCT) segment, in particular, experiencing explosive growth at an annual rate of 15.4% following COVID-19. Currently, clinical trials require an average of 10.5 years and an investment of $33 million*, with very low success rates. Major obstacles include participant medication adherence, data reliability issues from manual recording, and limitations in remote monitoring. InHandPlus introduces the industry's first automated medication management solution by integrating a smartwatch with a camera module and cutting-edge on-device AI. Beyond clinical trials, it enhances remote patient care with ChatGPT integration, bringing the power of a 'Doctor on Wrist' to life. Key Advantages of InHandPlus * Convenience: Automatic recording of medication usage simply by wearing the smartwatch * Reliability: On-device AI ensures accuracy above 99%* Versatility: Analyzes various forms of administration, including pills, injectables, and inhalers Want to learn more? Email us at biz@inhandplus.com Or send us a message on LinkedIn.* Based on an exchange rate of approximately 1 USD = 1,350 KRW 2030 5.7%, COVID-19 (DCT) 15.4%. AI. ChatGPT,"".*:*: AI 99%*: biz@inhandplus.com LinkedIn.